It has previously been observed that the tumor protective effect of Id-specific TCR transgenic CD4+ T cells can be partially overcome by injection of a greater number of myeloma cells, leading to tumor development in 60–80 % of wild-type TCR-transgenic mice [28]. This evidence concerns the gene CD4 and neoplasm.